Pharmacotherapy for hypertrophic cardiomyopathy
https://doi.org/10.21886/2712-8156-2023-4-4-6-13
Abstract
The presented review concerns modern approaches to drug therapy for hypertrophic cardiomyopathy. General issues of the treatment are touched upon, including lifestyle modification, maintaining adequate hydration and avoiding situations that increase obstruction. The role of traditionally used b-blockers and non-dihydropyridine calcium channel blockers in the treatment of the disease is described. Data on the use of disopyramide are presented, the treatment of which allows reducing the obstruction gradient, ameliorating clinical manifestations and improving diastolic function. Special attention is paid to a new class of drugs — cardiac myosin inhibitors: mavacamten and aficamten. The results of randomized clinical trials regarding to evaluating the efficacy of these drugs are reported. The review presents a modern view of the place of perhexiline, trimetazidine, ranolazine, eleclazine, angiotensin II receptor blockers, combination of sacubitril and valsartan in the therapy of hypertrophic cardiomyopathy.
About the Authors
G. A. Ignatenko
Donetsk State Medical University n. a. M. Gorky
Russian Federation
Russian Federation
Grigory A. Ignatenko - Dr. Sci. (Med.), Donetsk State Medical University n. a. M. Gorky.
Donetsk, Donetsk People’s Republic
G. G. Taradin
Donetsk State Medical University n. a. M. Gorky
Russian Federation
Russian Federation
Gennadiy G. Taradin - Cand. Sci. (Med.), Donetsk State Medical University n. a. M. Gorky.
Donetsk, Donetsk People’s Republic
L. V. Kononenko
Donetsk State Medical University n. a. M. Gorky
Russian Federation
Russian Federation
Ludmila V. Kononenko - Donetsk State Medical University n. a. M. Gorky.
Donetsk, Donetsk People’s Republic
References
1. Maron BJ, Ommen SR, Semsarian C, Spirito P, Olivotto I, Maron MS. Hypertrophic cardiomyopathy: present and future, with translation into contemporary cardiovascular medicine. J Am Coll Cardiol. 2014;64(1):83-99. doi: 10.1016/j.jacc.2014.05.003
2. Ommen SR, Mital S, Burke MA, Day SM, Deswal A, Elliott P, et al. 2020 AHA/ACC Guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: A report of the American college of cardiology/American heart association joint committee on clinical practice guidelines. J Am Coll Cardiol. 2020;76(25):e159-e240. doi: 10.1016/j.jacc.2020.08.045
3. Authors/Task Force members; Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014;35(39):2733-79. doi: 10.1093/eurheartj/ehu284
4. Габрусенко С.А., Гудкова А.Я., Козиолова Н.А., Александрова С.А., Берсенева М.И., Гордеев М.Л. и др. Гипертрофическая кардиомиопатия. Клинические рекомендации. 2020. Российский кардиологический журнал. 2021;26(5):4541. doi: 10.15829/1560-4071-2021-4541
5. Ватутин Н.Т., Тарадин Г.Г., Марон М.С. Гипертрофическая кардиомиопатия: генетические изменения, патогенез и патофизиология. Российский кардиологический журнал. 2014;(5):35-42. doi: 10.15829/1560-4071-2014-5-35-42
6. Raphael CE, Cooper R, Parker KH, Collinson J, Vassiliou V, Pennell DJ, et al. Mechanisms of myocardial ischemia in hypertrophic cardiomyopathy: insights from wave intensity analysis and magnetic resonance. J Am Coll Cardiol. 2016;68(15):1651-1660. doi: 10.1016/j.jacc.2016.07.751
7. Maron BJ, Rowin EJ, Maron MS. Hypertrophic cardiomyopathy: new concepts and therapies. Annu Rev Med. 2022;73:363-375. doi: 10.1146/annurev-med-042220-021539
8. Maron BJ, Desai MY, Nishimura RA, Spirito P, Rakowski H, Towbin JA, et al. Management of hypertrophic cardiomyopathy: JACC State-of-the-Art Review. J Am Coll Cardiol. 2022;79(4):390-414. doi: 10.1016/j.jacc.2021.11.021
9. Гудкова А.Я., Стрельцова А.А., Костарева А.А. Гипертрофическая кардиомиопатия: современные возможности фармакологических подходов к лечению. Терапевтический архив. 2019;91(9):129–136. doi: 10.26442/00403660.2019.09.000137
10. Packard E, de Feria A, Peshin S, Reza N, Owens AT. Contemporary therapies and future directions in the management of hypertrophic cardiomyopathy. Cardiol Ther. 2022;11(4):491-507. doi: 10.1007/s40119-022-00283-5
11. Geske JB, Ommen SR, Gersh BJ. Hypertrophic cardiomyopathy: clinical update. JACC Heart Fail. 2018;6(5):364-375. doi: 10.1016/j.jchf.2018.02.010
12. Dybro AM, Rasmussen TB, Nielsen RR, Andersen MJ, Jensen MK, Poulsen SH. Randomized trial of metoprolol in patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2021;78(25):2505-2517. doi: 10.1016/j.jacc.2021.07.065
13. Zampieri M, Berteotti M, Ferrantini C, Tassetti L, Gabriele M, Tomberli B, et al. Pathophysiology and treatment of hypertrophic cardiomyopathy: new perspectives. Curr Heart Fail Rep. 2021;18(4):169-179. doi: 10.1007/s11897-021-00523-0
14. Spoladore R, Fragasso G, Pannone L, Slavich M, Margonato A. Pharmacotherapy for the treatment of obstructive hypertrophic cardiomyopathy. Expert Opin Pharmacother. 2020;21(2):233-242. doi: 10.1080/14656566.2019.1702023
15. Batzner A, Schäfers HJ, Borisov KV, Seggewiß H. Hypertrophic obstructive cardiomyopathy. Dtsch Arztebl Int. 2019;116(4):47-53. doi: 10.3238/arztebl.2019.0047
16. Sanchez-Nadales A, Anampa-Guzmán A, Khan A. Disopyramide for hypertrophic cardiomyopathy. Cureus. 2019;11(4):e4526. doi: 10.7759/cureus.4526
17. Sherrid MV, Barac I, McKenna WJ, Elliott PM, Dickie S, Chojnowska L, et al. Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2005;45(8):1251-8. doi: 10.1016/j.jacc.2005.01.012
18. Toepfer CN, Garfinkel AC, Venturini G, Wakimoto H, Repetti G, Alamo L, et al. Myosin sequestration regulates sarcomere function, cardiomyocyte energetics, and metabolism, informing the pathogenesis of hypertrophic cardiomyopathy. Circulation. 2020;141(10):828-842. doi: 10.1161/CIRCULATIONAHA.119.042339
19. Autore C, Francia P, Tini G, Musumeci B. Old and new therapeutic solutions in the treatment of hypertrophic cardiomyopathy. Eur Heart J Suppl. 2023;25(Suppl B):B12-B15. doi: 10.1093/eurheartjsupp/suad060
20. Tuohy CV, Kaul S, Song HK, Nazer B, Heitner SB. Hypertrophic cardiomyopathy: the future of treatment. Eur J Heart Fail. 2020;22(2):228-240. doi: 10.1002/ejhf.1715
21. Olivotto I, Oreziak A, Barriales-Villa R, Abraham TP, Masri A, Garcia-Pavia P, et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2020;396(10253):759-769. doi: 10.1016/S0140-6736(20)31792-X
22. Wheeler MT, Olivotto I, Elliott PM, Saberi S, Owens AT, Maurer MS, et al. Effects of mavacamten on measures of cardiopulmonary exercise testing beyond peak oxygen consumption: a secondary analysis of the explorer-hcm randomized trial. JAMA Cardiol. 2023;8(3):240-247. doi: 10.1001/jamacardio.2022.5099
23. Desai MY, Owens A, Geske JB, Wolski K, Naidu SS, Smedira NG, et al. Myosin inhibition in patients with obstructive hypertrophic cardiomyopathy referred for septal reduction therapy. J Am Coll Cardiol. 2022;80(2):95-108. doi: 10.1016/j.jacc.2022.04.048
24. Ho CY, Mealiffe ME, Bach RG, Bhattacharya M, Choudhury L, Edelberg JM, et al. Evaluation of mavacamten in symptomatic patients with nonobstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2020;75(21):2649-2660. doi: 10.1016/j.jacc.2020.03.064
25. Dalo JD, Weisman ND, White CM. Mavacamten, a first-in-class cardiac myosin inhibitor for obstructive hypertrophic cardiomyopathy. Ann Pharmacother. 2023;57(4):489-502. doi: 10.1177/10600280221117812
26. Chuang C, Collibee S, Ashcraft L, Wang W, Vander Wal M, Wang X, et al. Discovery of aficamten (ck-274), a next-generation cardiac myosin inhibitor for the treatment of hypertrophic cardiomyopathy. J Med Chem. 2021;64(19):14142-14152. doi: 10.1021/acs.jmedchem.1c01290
27. Maron MS, Masri A, Choudhury L, Olivotto I, Saberi S, Wang A, et al. Phase 2 study of aficamten in patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2023;81(1):34-45. doi: 10.1016/j.jacc.2022.10.020
28. Abozguia K, Elliott P, McKenna W, Phan TT, Nallur-Shivu G, Ahmed I, et al. Metabolic modulator perhexiline corrects energy deficiency and improves exercise capacity in symptomatic hypertrophic cardiomyopathy. Circulation. 2010;122(16):1562-1569. doi: 10.1161/CIRCULATIONAHA.109.934059
29. Coats CJ, Pavlou M, Watkinson OT, Protonotarios A, Moss L, Hyland R, et al. Effect of trimetazidine dihydrochloride therapy on exercise capacity in patients with nonobstructive hypertrophic cardiomyopathy: a randomized clinical trial. JAMA Cardiol. 2019;4(3):230-235. doi: 10.1001/jamacardio.2018.4847
30. Gentry JL 3rd, Mentz RJ, Hurdle M, Wang A. Ranolazine for treatment of angina or dyspnea in hypertrophic cardiomyopathy patients (RHYME). J Am Coll Cardiol. 2016;68(16):1815-1817. doi: 10.1016/j.jacc.2016.07.758
31. Olivotto I, Camici PG, Merlini PA, Rapezzi C, Patten M, Climent V, et al. Efficacy of ranolazine in patients with symptomatic hypertrophic cardiomyopathy: The RESTYLE-HCM randomized, double-blind, placebo-controlled study. Circ Heart Fail. 2018;11(1):e004124. doi: 10.1161/CIRCHEARTFAILURE.117.004124
32. Palandri C, Santini L, Argirò A, Margara F, Doste R, Bueno-Orovio A, et al. Pharmacological management of hypertrophic cardiomyopathy: from bench to bedside. Drugs. 2022;82(8):889-912. doi: 10.1007/s40265-022-01728-w
33. Olivotto I, Hellawell JL, Farzaneh-Far R, Blair C, Coppini R, Myers J, et al. Novel approach targeting the complex pathophysiology of hypertrophic cardiomyopathy: the impact of late sodium current inhibition on exercise capacity in subjects with symptomatic hypertrophic cardiomyopathy (LIBERTY-HCM) Trial. Circ Heart Fail. 2016;9(3):e002764. doi: 10.1161/CIRCHEARTFAILURE.115.002764
34. Teekakirikul P, Eminaga S, Toka O, Alcalai R, Wang L, Wakimoto H, et al. Cardiac fibrosis in mice with hypertrophic cardiomyopathy is mediated by non-myocyte proliferation and requires Tgf-β. J Clin Invest. 2010;120(10):3520-3529. doi: 10.1172/JCI42028
35. Axelsson A, Iversen K, Vejlstrup N, Ho C, Norsk J, Langhoff L, et al. Efficacy and safety of the angiotensin II receptor blocker losartan for hypertrophic cardiomyopathy: the INHERIT randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2015;3(2):123-131. doi: 10.1016/S2213-8587(14)70241-4
36. Ho CY, Day SM, Axelsson A, Russell MW, Zahka K, Lever HM, et al. Valsartan in early-stage hypertrophic cardiomyopathy: a randomized phase 2 trial. Nat Med. 2021;27(10):1818-1824. doi: 10.1038/s41591-021-01505-4
37. Shimada YJ, Passeri JJ, Baggish AL, O'Callaghan C, Lowry PA, Yannekis G, et al. Effects of losartan on left ventricular hypertrophy and fibrosis in patients with nonobstructive hypertrophic cardiomyopathy. JACC Heart Fail. 2013;1(6):480-487. doi: 10.1016/j.jchf.2013.09.001
38. Abdelazeem B, Abbas KS, Ahmad S, Raslan H, Labieb F, Savarapu P. The effect of angiotensin II receptor blockers in patients with hypertrophic cardiomyopathy: an updated systematic review and meta-analysis of randomized controlled trials. Rev Cardiovasc Med. 2022;23(4):141. doi: 10.31083/j.rcm2304141
39. Pieske B, Wachter R, Shah SJ, Baldridge A, Szeczoedy P, Ibram G, et al; PARALLAX Investigators and Committee members. Effect of sacubitril/valsartan vs standard medical therapies on plasma NT-proBNP concentration and submaximal exercise capacity in patients with heart failure and preserved ejection fraction: The PARALLAX randomized clinical trial. JAMA. 2021;326(19):1919-1929. doi: 10.1001/jama.2021.18463
40. Tafelmeier M, Baessler A, Wagner S, Unsoeld B, Preveden A, Barlocco F, et al. Design of the SILICOFCM study: Effect of sacubitril/valsartan vs lifestyle intervention on functional capacity in patients with hypertrophic cardiomyopathy. Clin Cardiol. 2020;43(5):430-440. doi: 10.1002/clc.23346
Supplementary files
Review
For citations:
Ignatenko G.A., Taradin G.G., Kononenko L.V. Pharmacotherapy for hypertrophic cardiomyopathy. South Russian Journal of Therapeutic Practice. 2023;4(4):6-13. (In Russ.) https://doi.org/10.21886/2712-8156-2023-4-4-6-13
Views:
4726
Email this article 